NASDAQ:NXTCNextCure Stock Price, Forecast & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NXTC shares have decreased by 12.5% and is now trading at $33.45. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) announced its quarterly earnings data on Thursday, May, 7th. The company reported $0.33 EPS for the quarter, topping the Zacks' consensus estimate of ($0.44) by $0.77. The firm earned $22.38 million during the quarter, compared to analysts' expectations of $1.30 million. NextCure had a negative return on equity of 7.12% and a negative net margin of 65.22%. View NextCure's earnings history.

9 equities research analysts have issued 12-month price targets for NextCure's shares. Their forecasts range from $44.00 to $87.00. On average, they anticipate NextCure's stock price to reach $65.11 in the next year. This suggests a possible upside of 94.7% from the stock's current price. View analysts' price targets for NextCure.

News coverage about NXTC stock has been trending very negative recently, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NextCure earned a news sentiment score of -3.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutNextCure.

NextCure saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,260,000 shares, an increase of 7.7% from the April 30th total of 1,170,000 shares. Based on an average daily trading volume, of 224,300 shares, the days-to-cover ratio is presently 5.6 days. Currently, 7.9% of the company's shares are short sold. View NextCure's Current Options Chain.

Some companies that are related to NextCure include Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Biohaven Pharmaceutical (BHVN), Arrowhead Pharmaceuticals (ARWR), Deciphera Pharmaceuticals (DCPH), Amicus Therapeutics (FOLD), FibroGen (FGEN), PTC Therapeutics (PTCT), Arena Pharmaceuticals (ARNA), Axsome Therapeutics (AXSM), Uniqure (QURE), HUTCHISON CHINA/S (HCM), Amarin (AMRN), Taro Pharmaceutical Industries (TARO) and Apellis Pharmaceuticals (APLS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Amgen (AMGN), Alibaba Group (BABA), CVS Health (CVS), Dicerna Pharmaceuticals (DRNA), UnitedHealth Group (UNH), Honeywell International (HON), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T) and Arena Pharmaceuticals (ARNA).

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure's stock is owned by many different retail and institutional investors. Top institutional shareholders include Lord Abbett & CO. LLC (7.77%), Canaan Partners X LLC (7.37%), Alliancebernstein L.P. (4.56%), BlackRock Inc. (4.04%), Cormorant Asset Management LP (2.70%) and ArrowMark Colorado Holdings LLC (2.66%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View institutional ownership trends for NextCure.

NXTC stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Canaan Partners X LLC, Wellington Management Group LLP, ArrowMark Colorado Holdings LLC, Morgan Stanley, EAM Global Investors LLC, EAM Investors LLC, and JPMorgan Chase & Co.. View insider buying and selling activity for NextCure.

NXTC stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Jennison Associates LLC, Alliancebernstein L.P., State Street Corp, Geode Capital Management LLC, Trexquant Investment LP, HarbourVest Partners LLC, and BlackRock Inc.. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan. View insider buying and selling activity for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $33.45.

NextCure has a market capitalization of $920.54 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]